查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1439258

注射给药装置 - 全球市场回顾、竞争格局、市场预测 (2030)

Injectable Drug Delivery Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

全球注射给药装置市场规模预计到2023年将达到196.3亿美元，到2030年将达到372.2亿美元，2024-2030年预测期间复合年增长率为11.26%。对注射给药装置的需求主要由癌症、糖尿病和心血管疾病等慢性疾病的增加、自动注射器需求的增加、生物製剂和生物仿製药市场的增长以及患者对治疗的依从性推动。由于该领域对创新和技术进步的需求不断增长，它呈现出成长趋势。

注射给药市场动态

根据世界卫生组织（WHO）资料（2022年），2020年，乳癌226万例，肺癌221万例，大肠直肠癌193万例，摄护腺癌141万例，胃癌109万例。癌症报告了。

根据IDF Diabetes Atlas统计（2023 年），2021 年有 5.37 亿成年人患有糖尿病。预计到 2030 年，这一数字将增至 6.43 亿，到 2045 年将增至 7.83 亿。

根据British Heart Foundation（2022）提供的数据，2019年全球约有5.5亿人（每14人中就有1人）患有心臟和循环系统疾病，其中全球约有2亿人，其中包括9000万女性和约2.6亿男性。

因此，随着癌症、糖尿病和心血管疾病等慢性疾病盛行率的不断增加，化疗和胰岛素输送程序的增加，注射给药市场预计将扩大。

然而，药物传输系统中奈米颗粒引起的某些副作用以及与先进注射药物传输设备相关的高成本预计将限制预测期内的市场成长。

注射给药装置市场细分分析

在注射给药市场的产品类型部分，自动注射器可能会主导注射给药市场。该领域发生了无数的创新和发展。自动注射器的一些主要优点是患者使用起来非常方便且成本低。该产品是根据患者回馈而开发的，旨在让患者接触到适应性最强、易于使用、能够高精度给药的设备。近年来，患者对该设备的偏好有所增加。总体而言，自动注射器带来的好处和患者对自我给药的认识将导致这些设备的市场需求激增。

多项技术进步提高了患者对自动注射器的接受度。与传统的弹簧加载注射器相比，由液化氢氟烷 (HFA) 等液化气体提供动力，具有多种优势。主要优点是注射过程中获得恆定的力道。为了实现完整的注射，与典型的弹簧加载自动注射器相比，HFA 驱动的自动注射器往往需要更低的峰值力，因为力不会衰减。这使得注射器上的压力更小，并且药物输送期间的力量变化更小。

2019 年 10 月，Becton Dickinson 推出了 BD Intevia□，这是一款两级一次性自动注射器，这是一种整合了自动注射器和预充式注射器的坚固平台设备。该装置的开发是为了提高患者自我注射期间的易用性。此类产品开发活动对市场成长有正面影响。

因此，与其他产品类型相比，自动注射器提供的各种优势增加了患者对自动注射器的需求，导致自动注射器市场的快速成长。

本报告提供了全球注射给药装置市场的研究和分析，包括市场规模和预测、驱动因素和挑战、公司和产品概况。

目录

第1章 注射给药装置报告简介

第2章 注射给药装置的执行摘要

  • 调查范围
  • 市场概况
  • 竞争评估

第3章 监管分析

  • 美国
  • 欧洲
  • 日本
  • 中国

第4章 注射给药装置主要因素分析

  • 注射给药装置市场的驱动因素
    • 癌症、糖尿病和心血管疾病等慢性疾病的盛行率增加
    • 生物製剂和生物相似药市场的崛起
    • 对患者治疗依从性的需求不断增加
    • 技术创新与技术进步
  • 注射给药装置市场限制与挑战
    • 药物传输系统中奈米颗粒引起的某些副作用
    • 与先进的注射给药装置相关的高成本
  • 注射给药装置市场的机遇
    • 对一次性注射器和预充式註射器的需求不断增长

第5章 注射给药装置的波特五力分析

第6章 注射给药器械市场布局

  • 按产品类型
    • 自注射器
    • 无针注射器
    • 自动注射器
    • 穿戴式註射器
    • 胰岛素笔
  • 透过药物填充
    • 预填充装置
    • 灌装式装置
  • 重复使用性别
    • 可重复使用的装置
    • 免洗装置
  • 透过现场交付
    • 肌肉内
    • 皮内
    • 皮下
  • 按最终用户
    • 医院
    • 专科诊所
    • 居家护理环境
  • 按地区
    • 北美注射给药装置市场规模（2021-2030）
    • 欧洲注射给药装置市场规模（2021-2030）
    • 亚太地区注射给药装置市场规模（2021-2030）
    • 其他地区注射给药装置市场规模（2021-2030年）

第7章 注射给药器材公司及产品概况

  • Eli Lilly and Company
  • Biocon
  • Becton, Dickinson & Company
  • West Pharmaceutical Services, Inc.
  • Johnson & Johnson
  • Antares Pharma
  • AbbVie Inc.
  • Pfizer Inc.
  • Mylan N.V.
  • Vetter Pharma-Fertigung GmbH & Co.KG
  • Emperra GmbH
  • Gerresheimer AG
  • SCHOTT AG
  • Terumo Corporation
  • Teva Pharmaceutical Industries Ltd

第8章 KOL观点

第9章 专案方法

第10章 DelveInsight服务内容

第11章 关于 DelveInsight

第12章 免责声明与联络我们

Product Code: DIMDCL0047

Injectable Drug Delivery Devices Market By Product Type (Self-Injectors, Needle-Free, Auto Injectors, Wearable Injectors, and Insulin Pens), Drug Loading (Prefilled Injection Devices and Fillable Injection Devices), Reusability (Reusable and Disposable), Site Of Delivery (Intramuscular, Subcutaneous, and Intra Dermal), End-User (Hospitals, Specialty Clinics, and Homecare Settings), and Geography is expected to grow at a steady CAGR Forecast till 2030 owing to a rise observed in the demand for self-injectors and the rise in the incidence of chronic conditions such as cancer and diabetes amongst others

The global injectable drug delivery devices market was valued at USD 19.63 billion in 2023, growing at a CAGR of 11.26% during the forecast period from 2024 to 2030, to reach USD 37.22 billion by 2030. The demand for injectable drug delivery devices is primarily witnessing growth on account of the increasing incidences of chronic conditions such as cancer, diabetes, and cardiovascular disorders among others, increase in demand for self-injectors, increase in biologics and biosimilar market, rising need and demand for patient compliance to treatment and the rising innovations and technological advancement in this arena.

Injectable Drug Delivery Devices Market Dynamics:

According to the data cited by the World Health Organization 2022, worldwide around 2.26 million cases of breast, 2.21 million cases of lung, 1.93 million cases of colon and rectum, 1.41 million cases of prostate, and 1.09 million cases of stomach cancer were reported in 2020.

As per statistics by the IDF Diabetes Atlas (2023), 537 million adults were living with diabetes in 2021. This number is predicted to rise to 643 million by 2030 and 783 million by 2045.

As per the data provided by British Heart Foundation 2022, worldwide around 550 million which stands for 1 in 14 people were living with heart and circulatory diseases in 2019 and this includes about 290 million women and around 260 million men.

Hence, due to the rise in incidences of cancer, diabetes, and cardiovascular disorders among other chronic conditions, there will be a rise observed in the chemotherapy and insulin delivery procedures and hence the increase in the injectable drug delivery market.

However, certain side effects caused due to the nanoparticles of the drug delivery system and the high cost associated with advanced injectable drug delivery devices are expected to limit the market growth over the forecast period.

Injectable Drug Delivery Devices Market Segment Analysis:

Injectable Drug Delivery Devices Market by Product Type (Self-Injectors, Needle-Free, Auto Injectors, Wearable Injectors, and Insulin Pens), Drug Loading (Prefilled Injection Devices and Fillable Injection Devices), Reusability (Reusable and Disposable), Site Of Delivery (Intramuscular, Subcutaneous, and Intra Dermal), End-User (Hospitals, Specialty Clinics, and Homecare Settings), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the product type segment of the Injectable Drug Delivery Devices Market, self-injectors are likely to dominate the injectable drug delivery devices market. There have been innumerable innovations and developments that have taken place in this arena. Some profound advantages offered by self-injectors are that they are extremely convenient for patient use and are available at low costs. The product is built after patient feedback to expose patients to the most adaptable devices that can cater to the high precision of drug delivery and are easy to use. The preference for this device has lately increased among patients. Overall, the advantages offered by self-injectors and the awareness among patients of self-administration will lead to a surge in the market demand for these devices.

Several technological advancements have led to an increased acceptance of self-injectors among patients. The use of liquefied gas, for instance, liquefied hydrofluoroalkane (HFA), has acted as a power source presenting several advantages over the conventional spring-based injectors. The major advantage is that it tends to offer a constant force throughout the injection. To achieve full injection, the HFA-powered autoinjectors tend to require lower peak forces when compared with the typical spring autoinjector because the force does not tend to decay. This applies lower stresses on the syringe and results in a lower variation of force during drug delivery.

In October 2019, Becton Dickinson launched the two-step disposable autoinjector BD Intevia(TM), a robust platform device that combines an autoinjector and pre-fillable syringe in an integrated system. The device was developed to promote patient ease of use when self-injecting. Such product development activities are going to positively impact the market growth.

Hence, due to the various advantages offered by self-injectors in contrast to other product types, there will be an increase in demand among patients for these, leading to a surge in the self-injector market.

North America is expected to dominate the overall Injectable Drug Delivery Devices Market:

Among all the regions, North America is expected to account for the largest share of the injectable drug delivery devices market. This can be attributed to the rising numbers of chronic diseases, increasing research and developments, government initiatives to increase awareness about chronic conditions, and the rise in healthcare spending are predicted to be the major influencing factors in driving the overall growth of the market over the forecast period.

As per the figures mentioned by the American Cancer Society 2021, it was estimated that 1.9 million new cancer cases have been diagnosed in the United States in 2021. Also, according to the data provided by the Centers for Disease Control and Prevention (CDC) 2021, around 1,752,735 new cases of cancer were reported in the US in 2019. As per Globocan 2021 data, there were around 61,152 new cases of leukemia recorded in 2020 in the United States. As per the same source around 73, 652 cases of Non-Hodgkin lymphoma and 8,107 new cases of Hodgkin lymphoma were recorded in 2020 in the US.

The American Heart Association in 2021 projected that by 2035, more than 130 million US adults will have some type of heart disease.

Therefore, owing to the presence of a large patient pool in the country, the injectable drug delivery devices market is expected to bolster in the United States during the forecast period.

Injectable Drug Delivery Devices Market Key Players:

Some of the key market players operating in the injectable drug delivery devices market include Eli Lilly and Company, Biocon, Becton, Dickinson & Company, West Pharmaceutical Services, Inc., Johnson & Johnson, Antares Pharma, AbbVie Inc., Pfizer Inc., Mylan N.V., Vetter Pharma-Fertigung GmbH & Co.KG, Emperra GmbH, Gerresheimer AG, SCHOTT AG, Terumo Corporation and others.

Recent Developmental Activities in Injectable Drug Delivery Devices Market:

On August 21, 2022, Zydus Cadila's needle-free, plasmid DNA Covid vaccine received the Drug Controller General of India (DCGI) approval.

On November 13, 2019, Stevanato and Duoject entered auto-injector collaboration for manufacturing and promoting the emergency use 'Maverick' auto-injector.

On October 21, 2019, Becton Dickinson and Company, a leading global medical technology company announced the launch of BD Intevia(TM) 1mL two-step disposable autoinjector, a robust platform device combining autoinjector and pre-fillable syringe in one integrated system.

Key Takes Away from the Injectable Drug Delivery Devices Market Report Study

Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global injectable drug delivery devices market.

Various opportunities available for the other competitor in the injectable drug delivery devices market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for market growth in the coming future?

Target Audience who can be benefited from the Injectable Drug Delivery Devices Market Report Study

Injectable Drug Delivery Devices providers

Research organizations and consulting companies

Injectable Drug Delivery Devices-related organization, association, forum, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders

Various End-Users who want to know more about the injectable drug delivery devices market and the latest technological developments in the injectable drug delivery devices market.

Frequently Asked Questions for Injectable Drug Delivery Devices Market:

1. What are injectable drug delivery devices?

Injectable Drug Delivery devices comprise self-injectors, needle-free, auto injectors, and others. These devices help in drug delivery at targeted areas in the body. The devices tend to allow patients for easier administration of drugs without the need for any medical assistance.

2. What is the market for global injectable drug delivery devices?

The global injectable drug delivery devices market was valued at USD 19.63 billion in 2023, growing at a CAGR of 11.26% during the forecast period from 2024 to 2030, to reach USD 37.22 billion by 2030.

3. What are the drivers for global injectable drug delivery devices?

The major drivers driving the demand for injectable drug delivery devices are the rising incidences of chronic conditions, for instance, cancer, diabetes, and cardiovascular disorders among others, an increase in the demand for self-injectors, a rise in biologics and biosimilar market and the increasing need and demand for patient compliance to treatment and the rising innovations and technological advancement in this arena.

4. What are the key players operating in global injectable drug delivery devices?

Some of the key market players operating in the injectable drug delivery devices market include Eli Lilly and Company, Biocon, Becton, Dickinson & Company, West Pharmaceutical Services, Inc., Johnson & Johnson, Antares Pharma, AbbVie Inc., Pfizer Inc., Mylan N.V., Vetter Pharma-Fertigung GmbH & Co.KG, and others.

5. What regions have the highest share in the injectable drug delivery devices market?

North America is expected to dominate the overall injectable drug delivery devices market during the forecast period, 2024 to 2030. This domination is due to the increasing numbers of chronic diseases, rising research and developments, and increasing government initiatives to improve awareness about chronic conditions and the rise in healthcare spending.

Table of Contents

1. Injectable Drug Delivery Devices Report Introduction

2. Injectable Drug Delivery Devices Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment

3. Regulatory Analysis

  • 3.1. The United States
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Injectable Drug Delivery Devices Key Factors Analysis

  • 4.1. Injectable Drug Delivery Devices Market Drivers
    • 4.1.1. Increasing incidences of chronic conditions such as cancer, diabetes and cardiovascular disorders among others
    • 4.1.2. Increase in biologics and biosimilar market
    • 4.1.3. Rising need and demand for patient compliance to treatment
    • 4.1.4. Rising innovations and technological advancement
  • 4.2. Injectable Drug Delivery Devices Market Restraints and Challenges
    • 4.2.1. Certain side effects caused due to the nanoparticles of the drug delivery system
    • 4.2.2. High cost associated with advanced injectable drug delivery devices
  • 4.3. Injectable Drug Delivery Devices Market Opportunities
    • 4.3.1. Rising demand for disposable injecting devices and prefilled syringes

5. Injectable Drug Delivery Devices Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. Injectable Drug Delivery Devices Market Layout

  • 6.1. By Product Type
    • 6.1.1. Self-injectors
    • 6.1.2. Needle-free Injectors
    • 6.1.3. Auto Injectors
    • 6.1.4. Wearable Injectors
    • 6.1.5. Insulin Pens
  • 6.2. By Drug Loading
    • 6.2.1. Pre filled devices
    • 6.2.2. Fillable Devices
  • 6.3. By Reusability
    • 6.3.1. Reusable Devices
    • 6.3.2. Disposable Devices
  • 6.4. By On Site Delivery
    • 6.4.1. Intramuscular
    • 6.4.2. Intradermal
    • 6.4.3. Subcutaneous
  • 6.5. By End-User
    • 6.5.1. Hospitals
    • 6.5.2. Specialty Clinics
    • 6.5.3. Home care settings
  • 6.6. By Geography
    • 6.6.1. North America Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.1.1. United States Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.1.2. Canada Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.1.3. Mexico Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
    • 6.6.2. Europe Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.2.1. France Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.2.2. Germany Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.2.3. United Kingdom Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.2.4. Italy Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.2.5. Spain Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.2.6. Rest of Europe Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
    • 6.6.3. Asia-Pacific Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.3.1. China Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.3.2. Japan Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.3.3. India Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.3.4. Australia Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.3.5. South Korea Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.3.6. Rest of Asia Pacific Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
    • 6.6.4. Rest of the World (RoW Injectable Drug Delivery Devices Market Size in USD million (2021-2030)) Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.4.1. Middle East Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.4.2. Africa Injectable Drug Delivery Devices Market Size in USD million (2021-2030)
      • 6.6.4.3. South America Injectable Drug Delivery Devices Market Size in USD million (2021-2030)

7. Injectable Drug Delivery Devices Company and Product Profiles

  • 7.1. Eli Lilly and Company
    • 7.1.1. Company Overview
    • 7.1.2. Company Snapshot
    • 7.1.3. Financial Overview
    • 7.1.4. Product Listing
    • 7.1.5. Entropy
  • 7.2. Biocon
    • 7.2.1. Company Overview
    • 7.2.2. Company Snapshot
    • 7.2.3. Financial Overview
    • 7.2.4. Product Listing
    • 7.2.5. Entropy
  • 7.3. Becton, Dickinson & Company
    • 7.3.1. Company Overview
    • 7.3.2. Company Snapshot
    • 7.3.3. Financial Overview
    • 7.3.4. Product Listing
    • 7.3.5. Entropy
  • 7.4. West Pharmaceutical Services, Inc.
    • 7.4.1. Company Overview
    • 7.4.2. Company Snapshot
    • 7.4.3. Financial Overview
    • 7.4.4. Product Listing
    • 7.4.5. Entropy
  • 7.5. Johnson & Johnson
    • 7.5.1. Company Overview
    • 7.5.2. Company Snapshot
    • 7.5.3. Financial Overview
    • 7.5.4. Product Listing
    • 7.5.5. Entropy
  • 7.6. Antares Pharma
    • 7.6.1. Company Overview
    • 7.6.2. Company Snapshot
    • 7.6.3. Financial Overview
    • 7.6.4. Product Listing
    • 7.6.5. Entropy
  • 7.7. AbbVie Inc.
    • 7.7.1. Company Overview
    • 7.7.2. Company Snapshot
    • 7.7.3. Financial Overview
    • 7.7.4. Product Listing
    • 7.7.5. Entropy
  • 7.8. Pfizer Inc.
    • 7.8.1. Company Overview
    • 7.8.2. Company Snapshot
    • 7.8.3. Financial Overview
    • 7.8.4. Product Listing
    • 7.8.5. Entropy
  • 7.9. Mylan N.V.
    • 7.9.1. Company Overview
    • 7.9.2. Company Snapshot
    • 7.9.3. Financial Overview
    • 7.9.4. Product Listing
    • 7.9.5. Entropy
  • 7.10. Vetter Pharma-Fertigung GmbH & Co.KG
    • 7.10.1. Company Overview
    • 7.10.2. Company Snapshot
    • 7.10.3. Financial Overview
    • 7.10.4 Product Listing
    • 7.10.5. Entropy
  • 7.11. Emperra GmbH
    • 7.11.1. Company Overview
    • 7.11.2. Company Snapshot
    • 7.11.3. Financial Overview
    • 7.11.4. Product Listing
    • 7.11.5. Entropy
  • 7.12. Gerresheimer AG
    • 7.12.1. Company Overview
    • 7.12.2. Company Snapshot
    • 7.12.3. Financial Overview
    • 7.12.4. Product Listing
    • 7.12.5. Entropy
  • 7.13. SCHOTT AG
    • 7.13.1. Company Overview
    • 7.13.2. Company Snapshot
    • 7.13.3. Financial Overview
    • 7.13.4. Product Listing
    • 7.13.5. Entropy
  • 7.14. Terumo Corporation
    • 7.14.1. Company Overview
    • 7.14.2. Company Snapshot
    • 7.14.3. Financial Overview
    • 7.14.4. Product Listing
    • 7.14.5. Entropy
  • 7.15. Teva Pharmaceutical Industries Ltd
    • 7.15.1. Company Overview
    • 7.15.2. Company Snapshot
    • 7.15.3. Financial Overview
    • 7.15.4. Product Listing
    • 7.15.5. Entropy

8. KOL Views

9. Project Approach

10. DelveInsight Capabilities

11. About DelveInsight

12. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Injectable Drug Delivery Devices Market in Global (2021-2030)
  • Table 3: Injectable Drug Delivery Devices Market in Global by Product Type (2021-2030)
  • Table 4: Injectable Drug Delivery Devices Market in Global by Drug Loading (2021-2030)
  • Table 5: Injectable Drug Delivery Devices Market in Global by Reusability (2021-2030)
  • Table 6: Injectable Drug Delivery Devices Market in Global by On Site Delivery (2021-2030)
  • Table 7: Injectable Drug Delivery Devices Market in Global by End-User (2021-2030)
  • Table 8: Injectable Drug Delivery Devices Market in Global by Geography (2021-2030)
  • Table 9: Injectable Drug Delivery Devices Market in North America (2021-2030)
  • Table 10: Injectable Drug Delivery Devices Market in the US (2021-2030)
  • Table 11: Injectable Drug Delivery Devices Market in Canada (2021-2030)
  • Table 12: Injectable Drug Delivery Devices Market in Mexico (2021-2030)
  • Table 13: Injectable Drug Delivery Devices Market in Europe (2021-2030)
  • Table 14: Injectable Drug Delivery Devices Market in France (2021-2030)
  • Table 15: Injectable Drug Delivery Devices Market in Germany (2021-2030)
  • Table 16: Injectable Drug Delivery Devices Market in United Kingdom (2021-2030)
  • Table 17: Injectable Drug Delivery Devices Market in Italy (2021-2030)
  • Table 18: Injectable Drug Delivery Devices Market in Spain (2021-2030)
  • Table 19: Injectable Drug Delivery Devices Market in Rest of Europe (2021-2030)
  • Table 20: Injectable Drug Delivery Devices Market in Asia-Pacific (2021-2030)
  • Table 21: Injectable Drug Delivery Devices Market in China (2021-2030)
  • Table 22: Injectable Drug Delivery Devices Market in Japan (2021-2030)
  • Table 23: Injectable Drug Delivery Devices Market in India (2021-2030)
  • Table 24: Injectable Drug Delivery Devices Market in Australia (2021-2030)
  • Table 25: Injectable Drug Delivery Devices Market in South Korea (2021-2030)
  • Table 26: Injectable Drug Delivery Devices Market in Rest of Asia-Pacific (2021-2030)
  • Table 27: Injectable Drug Delivery Devices Market in Rest of the World (2021-2030)
  • Table 28: Injectable Drug Delivery Devices Market in Middle East (2021-2030)
  • Table 29: Injectable Drug Delivery Devices Market in Africa (2021-2030)
  • Table 30: Injectable Drug Delivery Devices Market in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Injectable Drug Delivery Devices Market in Global (2021-2030)
  • Figure 3: Injectable Drug Delivery Devices Market in Global by Product Type (2021-2030)
  • Figure 4: Injectable Drug Delivery Devices Market in Global by Drug Loading (2021-2030)
  • Figure 5: Injectable Drug Delivery Devices Market in Global by Reusability (2021-2030)
  • Figure 6: Injectable Drug Delivery Devices Market in Global by On Site Delivery (2021-2030)
  • Figure 7: Injectable Drug Delivery Devices Market in Global by End-User (2021-2030)
  • Figure 8: Injectable Drug Delivery Devices Market in Global by Geography (2021-2030)
  • Figure 9: Injectable Drug Delivery Devices Market in North America (2021-2030)
  • Figure 10: Injectable Drug Delivery Devices Market in the US (2021-2030)
  • Figure 11: Injectable Drug Delivery Devices Market in Canada (2021-2030)
  • Figure 12: Injectable Drug Delivery Devices Market in Mexico (2021-2030)
  • Figure 13: Injectable Drug Delivery Devices Market in Europe (2021-2030)
  • Figure 14: Injectable Drug Delivery Devices Market in France (2021-2030)
  • Figure 15: Injectable Drug Delivery Devices Market in Germany (2021-2030)
  • Figure 16: Injectable Drug Delivery Devices Market in United Kingdom (2021-2030)
  • Figure 17: Injectable Drug Delivery Devices Market in Italy (2021-2030)
  • Figure 18: Injectable Drug Delivery Devices Market in Spain (2021-2030)
  • Figure 19: Injectable Drug Delivery Devices Market in Rest of Europe (2021-2030)
  • Figure 20: Injectable Drug Delivery Devices Market in Asia-Pacific (2021-2030)
  • Figure 21: Injectable Drug Delivery Devices Market in China (2021-2030)
  • Figure 22: Injectable Drug Delivery Devices Market in Japan (2021-2030)
  • Figure 23: Injectable Drug Delivery Devices Market in India (2021-2030)
  • Figure 24: Injectable Drug Delivery Devices Market in Australia (2021-2030)
  • Figure 25: Injectable Drug Delivery Devices Market in South Korea (2021-2030)
  • Figure 26: Injectable Drug Delivery Devices Market in Rest of Asia-Pacific (2021-2030)
  • Figure 27: Injectable Drug Delivery Devices Market in Rest of the World (2021-2030)
  • Figure 28: Injectable Drug Delivery Devices Market in Middle East (2021-2030)
  • Figure 29: Injectable Drug Delivery Devices Market in Africa (2021-2030)
  • Figure 30: Injectable Drug Delivery Devices Market in South America (2021-2030)
  • Figure 31: Market Drivers
  • Figure 32: Market Barriers
  • Figure 33: Market Opportunities
  • Figure 34: PORTER'S Five Force Analysis